Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 4/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.61 |
| ▸ | POLB | P06746 | 1/20 | 0.61 |
| ▸ | GFER | P55789 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3306625 | 0.86 | KDM4E (0.59) | EGFRKDM4EMAPTTSHRMEN1 | |
| SCHEMBL2272671 | 0.85 | MEN1 (0.62) | KDM4EMAPTTSHRMEN1KMT2A | |
| SCHEMBL3306629 | 0.83 | KDM4E (0.56) | EGFRKDM4EMAPTTSHRMEN1 | |
| SCHEMBL29110691 | 0.83 | MEN1 (0.82) | KDM4EMAPTTSHRMEN1KMT2A | |
| SCHEMBL28051926 | 0.83 | KDM4E (0.58) | KDM4EMAPTTSHRMEN1KMT2A | |
| SCHEMBL9204840 | 0.82 | EGFR (0.68) | EGFRKDM4EMAPTMEN1KMT2A | |
| SCHEMBL7203206 | 0.81 | MEN1 (0.57) | KDM4EMAPTTSHRMEN1KMT2A | |
| SCHEMBL8166723 | 0.81 | KDM4E (0.60) | EGFRKDM4EMAPTTSHRMEN1 | |
| SCHEMBL12091798 | 0.79 | ALDH1A1 (0.66) | EGFRKDM4EMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL27967619 | 0.78 | KDM4E (0.52) | EGFRKDM4EMAPTTSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5229413-A | Nervous system disorders | G. D. SEARLE & CO. (US) | 1993-07-20 | — | — | US | claimed |
| EP-0396124-A2 | Compositions containing indole-2-carboxylate compounds for treatment of CNS disorders | G.D. Searle & Co. (US) | 1990-11-07 | — | — | EP | claimed |
| US-20250288544-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | PARIS SCIENCES ET LETTRES - QUARTIER LATIN (FR) | 2025-09-18 | — | — | US | disclosed |
| US-12318358-B2 | Probenecid for use in treating epileptic diseases, disorders or conditions | PARIS SCIENCES ET LETTRES (FR) | 2025-06-03 | — | — | US | disclosed |
| CN-111386107-A | Use of probenecid in the treatment of an epileptic disease, disorder or condition | 巴黎科技与文学─拉丁区 | 2020-07-07 | — | — | CN | disclosed |
| US-20200163916-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | PARIS SCIENCES ET LETTRES - QUARTIER LATIN (FR) | 2020-05-28 | — | — | US | disclosed |
| EP-3651758-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | Paris Sciences et Lettres - Quartier Latin (FR) | 2020-05-20 | — | — | EP | disclosed |
| WO-2019012109-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | PARIS SCIENCES ET LETTRES - QUARTIER LATIN (FR) | 2019-01-17 | — | — | WO | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
| US-5229413-A | Nervous system disorders | G. D. SEARLE & CO. (US) | 1993-07-20 | — | — | US | disclosed |
| US-5137910-A | Compositions containing indole-2-carboxylate compounds for treatment of CNS disorders | C.D. SEARLE & CO. (US) | 1992-08-11 | — | — | US | disclosed |
| EP-0396124-A2 | Compositions containing indole-2-carboxylate compounds for treatment of CNS disorders | G.D. Searle & Co. (US) | 1990-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200163916-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | NLN, CLN6, SLC1A2 | EGFR 3922/4885KDM4E 4411/4885MAPT 129/4885 |
| US-20250288544-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | NLN, CLN6, SLC1A2 | EGFR 3922/4885KDM4E 4411/4885MAPT 129/4885 |
| US-12318358-B2 | Probenecid for use in treating epileptic diseases, disorders or conditions | NLN, CLN6, SLC1A2 | EGFR 3922/4885KDM4E 4411/4885MAPT 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.